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Supplementary Figures 
Supplementary Figure 1.  Study design. Meta analysis of genome-wide 
association data was performed in stage 1 across all the cohorts listed. Twenty 
SNPs representing loci most associated with SBP or DBP were selected for follow up 
(stage 2). Twelve SNPs were directly genotyped (2a), all twenty SNPs were tested 
for replication in silico (2b). 
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Supplementary Figure 2.  Panel A. Quantile-quantile plots of association results 
by cohort and overall.  Meta-analysis of 2,497,993 autosomal SNPs in 34,433 
individuals was performed using inverse variance weighting after cohort-specific 
genomic control.  Shown are plots of -log10(P) of association tests for diastolic and 
systolic blood pressure for each cohort in gender-specific analysis and for overall 
meta-analysis results.  λGC before genomic control was 1.08 for systolic and 1.07 
for diastolic blood pressure for the overall meta-analysis.  Panel B.  Association 
results for systolic and diastolic blood pressure.  Plotted are the -log10(P) of results 
for 2,497,993 SNPs after genomic control of meta-analysis results for 34,433 
individuals for systolic (a) and diastolic blood pressure (b).  Red squares denote 
SNPs that achieved genome-wide significance in final meta-analysis of results from 
stages, 1, 2a, 2b.  Note that loci 10q21 and 15q24 show genome-wide significant 
SNPs that are not the strongest SNPs at the locus.  These SNPs were selected for 
validation genotyping at an interim analysis and are shown throughout the text for 
consistency.  Note that two independent loci on 17q21 are associated with blood 
pressure, one with SBP and one with DBP. 
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Supplementary Table 1.  Global BPgen Stage 1 genome-wide genotyping, 
imputation and genotype-phenotype analysis by cohort.  Shown are the 
genotyping platforms, filters applied to individuals and SNPs (if any) before 
imputation, imputation software and genotype-phenotype association software.  
Lambda estimates are shown for SBP and DBP in cases (not analyzed in stage 1) 
and controls separately for men and women.  All individual cohort association 
results underwent genomic control before meta-analysis.
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Cohort Platform 
Calling 
algorithm 
Indiv 
Callrate 
Before 
Imp’n 
SNP 
Callrate 
Before 
Imp’n 
SNP 
HWE 
Before 
Imp’n 
SNP MAF 
Before 
Imp’n 
Other 
filter 
# SNPs 
For 
Imp’n 
Imputation 
software 
NCBI; 
HapMap 
CEU 
Genotype-
phenotype 
software 
Lambda 
SBP 
men/women 
controls 
Lambda 
SBP 
men/women 
cases 
Lambda 
DBP 
men/women 
controls 
Lambda 
DBP 
men/women 
cases 
B58C- 
WTCCC 
Affymetrix 
500K 
CHIAMO >0.97 
>0.95 
MAF>0.05 
>0.99 
MAF<0.05 
5.7E-7 none NA 490,032 IMPUTE 35; v21 SNPTEST 1.017/1.007 NA 1.015/1.000 NA 
B58C-
T1DGC 
Illumina 550K ILLUMINUS >0.98 none none none 
SNPs 
mapping 
to >1 
locus in 
the 
genome 
539,548 
MACH 
V1.0.13 
35; v21 
ProbABEL 
v0.0-5b 
1.00/1.00 NA 1.01/1.00 NA 
BLSA Illumina 550K Beadstudio >0.97 >0.99 >1E-4 >0.01 NA 501,764 MACH 
v1.0.15 
35; v21 Merlin 
offline 
1.037/1.012 NA 1.054/1.029 NA 
CoLaus 
Affymetrix 
500K 
BRLMM >0.95 >0.70 >1E-7 >0 NA 390,631 IMPUTE v0.2 35; v21 
custom 
C++ 
0.998/0.998 NA 1.001/1.006 NA 
DGI Affymetrix 
500K 
BRLMM NA >0.95 >1E-6 in 
controls 
≥0.01 
SNPs 
mapping 
to >1 
locus in 
the 
genome 
378,860 MACH v1.0.9 35; V21 SNPTEST 1.012/1.005 0.985/0.988 1.001/0.985 0.989/0.995 
EPIC-
Norfolk-
GWAS 
Affymetrix 
500K 
BRLMM ≥0.94 ≥0.90 >1E-6 ≥0.01 NA 397,438 IMPUTE 35; v21 SNPTEST 1.001/1.008 0.996/1.011 0.989/1.010 0.976/1.002 
Fenland 
AffymetrixSNP 
5.0 
BRLMM ≥0.94 ≥0.90 >1E-6 ≥0.01 NA 362,059 IMPUTEv0.4.2 36; V22 SNPTEST NA NA NA NA 
FUSION 
Illumina 
HumanHap 
300 
Beadstudio, 
clustering 
with 
FUSION 
>0.975 ≥0.90 >1E-6 >0.01 
>3 
Mendel 
or 
duplicate 
errors 
304,581 MACH 35; v21 Merlin 0.998/1.002 1.018/0.989 1.002/1.005 1.007/1.009 
InCHIANTI Illumina 550K Beadstudio >0.97 >0.99 >1E-4 >0.01 NA 484,115 
MACH 
v1.0.15 
35; v21 
Merlin 
offline 
0.995/1.007 NA 0.992/1.010 NA 
KORA 
Affymetrix 
500K 
BRLMM 
>0.93 
each chip 
>0.90  ≥0.01 NA  MACH v1.0.9 35; v21 PLINK 1.014/0.992 NA 1.009/1.004 NA 
MIGen 
Affymetrix 6.0 
BirdSuite1 ≥0.95 ≥0.95 ≥1E-6 ≥0.01 
close 
750,407 MACH v1.013 36; v22 SNPTEST 0.999/1.036 NA 0.992/1.017 NA 
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(1M) relatives 
NFBC66 Illumina 370 Beadstudio NA >0.95 >1E-4 ≥0.01 NA 328,007 IMPUTE 35; v21 SNPTEST 1.02/1.03 NA 1.01/1.03 NA 
PROCARDIS Illumina 1M Bead studio >0.95 >0.95 >1E-3 None NA 882,598 
IMPUTE 
v0.3.2 
36; v22 SNPTEST 0.997/1.025 0.999/1.008 0.988/1.020 1.007/0.999 
SardiNIA 
Affymetrix 
500 
BRLMM >0.95 >0.95 >1E-6 >0.01 NA 356,359 
MACH 
v1.0.15 
35; v21 
Merlin 
offline 
1.14 NA 1.14 NA 
SHIP 
Affymetrix 
SNP6.0 
BirdsuiteV2 >0.92 NA NA NA 
QC CR 
≥0.86 869,224 
IMPUTE 
v0.5.0 
36; v22 SNPTEST NA NA NA NA 
SUVIMAX Illumina 317K Beadstudio >0.94 NA NA NA NA 302,607 
IMPUTE 
v0.3.2 
35; v21 
Custom 
C++ 
1.005/0.998 NA 1.017/0.996 NA 
TWINS UK Illumina 317K Beadstudio NA >0.95 
>1E-6 in 
controls 
≥0.01 
SNPs 
mapping 
>1 loci 
 
Impute V 
0.4.2 
36; CEU 
v22 
SNPTEST NA/1.000 NA NA/1.006 NA 
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Supplementary Table 2.  Follow up genotyping in up to 71,225 European ancestry individuals from 13  
cohort samples and up to 12,889 Indian Asians.  Shown are results for the SNPs selected for follow up 
genotyping in stage 2a.  See Methods and Supplementary Methods for details on individual replication studies.  The 
cohorts are: The Utrecht Atherosclerosis Risk in Young Adults (AYRA), British Genetics of Hypertension study 
normotensive controls (BRIGHT NT), EPIC-Italy, EPIC-Norfolk-replication cohort (EPIC-Norfolk-REP), Finrisk97, 
FUSION2, London Life Sciences Population (LOLIPOP)-European ancestry (-EA) or -Indian Asian ancestry (-IA), 
Malmö Diet and Cancer Cardiovascular Cohort (MDC), Malmö Preventive Project (MPP), Metabolic syndrome in Men 
(METSIM), Prevention of REnal and Vascular ENd stage Disease (PREVEND), PROSPECT-EPIC cohort and Utrecht 
Health Project (UHP).  Bold indicates the meta-analysis results across all European ancestry samples using inverse 
variance weighting.    
 
SNP ID Cohort 
Coded allele 
frequency 
Effect (mmHg) SE P N 
rs17367504 ARYA 0.17 -0.80 0.82 0.33 688 
MTHFR/NPPA BRIGHT NT 0.17 -0.69 0.47 0.14 1,937 
SBP LOLIPOP-EA 0.16 -0.63 0.45 0.16 5,939 
Coded allele: G PREVEND 0.16 -1.25 0.40 0.002 7,091 
Noncoded allele: A PROSPECT-EPIC 0.17 -0.03 1.00 0.97 1,585 
 UHP 0.16 -1.69 0.68 0.01 2,511 
 Pooled European ancestry 0.16 -0.93 0.22 2x10-5 19,751 
 LOLIPOP-IA 0.17 -0.52 0.31 0.09 12,756 
rs11191548 ARYA 0.94 0.47 1.26 0.71 729 
CYP17A1 EPIC-Italy 0.90 1.57 0.62 0.01 3,680 
SBP EPIC-Norfolk-REP 0.92 1.42 0.36 1x10-4 14,854 
Coded allele: T Finrisk97 0.92 1.82 0.54 7x10-4 7,019 
Noncoded allele: C FUSION2 0.92 2.48 1.50 0.10 2,477 
 LOLIPOP-EA 0.92 -0.40 0.61 0.51 6,024 
 MDC-CC 0.89 1.80 0.58 2x10-3 5,332 
 METSIM 0.93 1.37 0.60 0.02 6,161 
 MPP 0.89 1.04 0.27 1x10-4 13,585 
 PREVEND 0.92 0.90 0.52 0.09 7,204 
 PROSPECT-EPIC 0.92 1.24 1.36 0.36 1,621 
 UHP 0.92 1.38 0.91 0.13 2,539 
 Pooled European ancestry 0.91 1.19 0.15 9x10-15 71,225 
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 LOLIPOP-IA 0.79 0.76 0.29 0.008 12,889 
rs12946454 ARYA 0.23 -0.37 0.75 0.62 700 
PLCD3 LOLIPOP-EA 0.27 0.33 0.37 0.37 5,981 
SBP PREVEND 0.24 0.56 0.35 0.11 7,082 
Coded allele: T PROSPECT-EPIC 0.25 1.23 0.84 0.14 1,598 
Noncoded allele: A UHP 0.24 0.40 0.57 0.49 2,516 
 Pooled European ancestry 0.25 0.43 0.21 0.045 17,877 
 LOLIPOP-IA 0.29 0.21 0.26 0.42 12,776 
rs6544619 ARYA 0.45 0.17 0.44 0.71 708 
HAAO LOLIPOP-EA 0.43 -0.23 0.19 0.24 6,002 
DBP PREVEND 0.44 -0.54 0.21 0.01 7,091 
Coded allele: T PROSPECT-EPIC 0.44 0.07 0.42 0.88 1,569 
Noncoded allele: C UHP 0.42 -0.17 0.32 0.59 2,516 
 Pooled European ancestry 0.44 -0.27 0.12 0.02 17,886 
 LOLIPOP-IA 0.49 -0.03 0.14 0.82 12,877 
rs1918974 ARYA 0.56 0.03 0.42 0.94 700 
MDS1 BRIGHT NT 0.55 0.04 0.24 0.86 1,956 
DBP Finrisk97 0.57 -0.41 0.18 0.02 7,014 
Coded allele: T LOLIPOP-EA 0.54 -0.16 0.22 0.47 4,522 
Noncoded allele: C PREVEND 0.53 -0.18 0.15 0.22 7,161 
 PROSPECT-EPIC 0.55 -0.01 0.41 0.98 1,599 
 UHP 0.52 -0.17 0.32 0.59 2,513 
 Pooled European ancestry 0.55 -0.18 0.08 0.04 26,910 
 LOLIPOP-IA 0.49 -0.30 0.14 0.03 12,757 
rs16998073 ARYA 0.31 0.65 0.47 0.16 722 
FGF5 BRIGHT NT 0.27 0.19 0.27 0.48 1,943 
DBP EPIC-Italy 0.25 0.09 0.26 0.74 3,701 
Coded allele: T EPIC-Norfolk-REP 0.29 0.39 0.14 0.01 15,013 
Noncoded allele: A Finrisk97 0.28 1.14 0.20 2x10-8 7,023 
 FUSION2 0.31 0.32 0.44 0.47 2,477 
 LOLIPOP-EA 0.30 0.38 0.21 0.07 6,017 
 MDC-CC 0.35 0.38 0.20 0.06 5,321 
 PREVEND 0.30 0.67 0.17 7x10-5 7,159 
 PROSPECT-EPIC 0.28 0.81 0.46 0.08 1,610 
 UHP 0.29 0.29 0.35 0.41 2,522 
 Pooled European ancestry 0.29 0.50 0.07 6x10-13 53,508 
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 LOLIPOP-IA 0.28 0.54 0.16 5x10-4 12,881 
rs10156056 ARYA 0.89 0.04 0.67 0.95 726 
IL6 FUSION2 0.81 0.78 0.50 0.12 2,477 
DBP LOLIPOP-EA 0.88 0.26 0.30 0.39 6,023 
Coded allele: G METSIM 0.78 -0.16 0.22 0.46 6,161 
Noncoded allele: C PREVEND 0.88 0.15 0.23 0.53 7,212 
 PROSPECT-EPIC 0.89 -0.18 0.66 0.78 1,604 
 UHP 0.89 -0.14 0.49 0.77 2,539 
 Pooled European ancestry 0.85 0.07 0.13 0.57 26,742 
 LOLIPOP-IA 0.89 0.07 0.22 0.75 12,853 
rs7098454 ARYA 0.74 0.13 0.49 0.79 726 
ADRB1 FUSION2 0.76 -0.16 0.46 0.73 2,477 
DBP LOLIPOP-EA 0.75 -0.09 0.22 0.70 6,006 
Coded allele: T MDC-CC 0.76 -0.37 0.22 0.09 5,308 
Noncoded allele: A METSIM 0.76 -0.32 0.21 0.13 6,161 
 PREVEND 0.68 -0.24 0.18 0.17 7,173 
 PROSPECT-EPIC 0.75 -0.64 0.47 0.17 1,621 
 UHP 0.74 -0.04 0.36 0.92 2,538 
 Pooled European ancestry 0.74 -0.24 0.09 0.01 32,010 
 LOLIPOP-IA 0.72 0.13 0.15 0.47 12,823 
rs1530440 ARYA 0.19 0.10 0.56 0.85 703 
C10orf107 BRIGHT NT 0.19 0.35 0.31 0.26 1,948 
DBP Finrisk97 0.20 -0.27 0.23 0.22 7,021 
Coded allele: T LOLIPOP-EA 0.18 -0.74 0.29 0.01 5,966 
Noncoded allele: C PREVEND 0.17 -0.51 0.20 0.01 7,149 
 PROSPECT-EPIC 0.17 0.43 0.55 0.43 1,590 
 UHP 0.18 0.16 0.41 0.69 2,528 
 Pooled European ancestry 0.18 -0.21 0.11 0.05 26,905 
 LOLIPOP-IA 0.15 0.03 0.19 0.87 12,781 
rs653178 ARYA 0.50 -1.07 0.43 0.01 687 
ATXN2/SH2B3 BRIGHT NT 0.52 0.23 0.24 0.35 1,912 
DBP LOLIPOP-EA 0.52 -0.91 0.19 2x10-6 5,939 
Coded allele:  PREVEND 0.56 -0.47 0.15 0.002 7,106 
 PROSPECT-EPIC 0.53 0.04 0.43 0.92 1,544 
 UHP 0.53 0.30 0.31 0.33 2,501 
 Pooled European ancestry 0.54 -0.40 0.10 3x10-5 19,689 
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 LOLIPOP-IA 0.89 0.18 0.22 0.40 12,760 
rs1378942 ARYA 0.35 0.65 0.45 0.14 726 
CYP1A2 EPIC-Italy 0.38 0.24 0.23 0.30 3,720 
DBP EPIC-Norfolk-REP 0.33 0.29 0.14 0.04 13,936 
Coded allele: C Finrisk97 0.45 0.38 0.18 0.04 7,019 
Noncoded allele: A FUSION2 0.44 0.57 0.79 0.47 2,477 
 LOLIPOP-EA 0.34 0.50 0.20 0.01 5,994 
 MDC-CC 0.31 0.40 0.20 0.05 5,311 
 METSIM 0.44 0.92 0.33 0.005 6,161 
 MPP 0.32 0.24 0.11 0.03 14,436 
 PREVEND 0.25 0.72 0.16 1x10-5 7,168 
 PROSPECT-EPIC 0.33 0.53 0.44 0.22 1,611 
 UHP 0.31 0.77 0.33 0.02 2,527 
 Pooled European ancestry 0.35 0.41 0.06 2x10-12 71,086 
 LOLIPOP-IA 0.77 0.22 0.16 0.17 12,858 
rs16948048 ARYA 0.36 0.29 0.45 0.51 694 
ZNF652/PHB BRIGHT NT 0.37 0.43 0.26 0.10 1,937 
DBP LOLIPOP-EA 0.37 -0.15 0.20 0.46 5,958 
Coded allele: G PREVEND 0.37 0.35 0.16 0.03 7,080 
Noncoded allele: A PROSPECT-EPIC 0.38 0.78 0.43 0.07 1,591 
 UHP 0.37 0.11 0.33 0.73 2,492 
 Pooled European ancestry 0.37 0.23 0.10 0.02 19,752 
 LOLIPOP-IA 0.16 -0.17 0.19 0.37 12,779 
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Supplementary Table 3.  Results of in silico exchange of 10 SBP and 10 DBP Global BPgen results with CHARGE.  Shown are the top SNPs at each 
locus with association results in Global BPgen and in CHARGE for the same coded allele.  The pooled test of association was determined using inverse variance 
weighted meta-analysis. The coded allele is the allele to which the beta (effect) estimate refers; for a SNP coded AA=0, AG=1, GG=2, G is the coded allele.  
SNPs in bold were selected for validation genotyping.  The SNP rs1918974 at the locus containing MDS1 was selected for genotyping at an interim analysis at 
which the strength of association in Global BPgen was stronger and was retained in the list despite weaker association in the final stage 1 meta-analysis, 
displacing the 10th SNP for DBP.  Loci that overlap between CHARGE and Global BPgen top ten lists are indicated with asterisks.   
SNP ID Chr 
Position 
NCBI35 
Genes of 
interest 
Coded 
allele 
Non-coded 
allele 
Coded 
Allele 
freq 
Effect  
(SE) 
mmHg 
P N 
Coded 
allele 
freq 
Effect 
(SE) 
mmHg 
P N 
Effect 
(SE) 
mmHg 
P N 
Systolic blood pressure Global BPgen CHARGE  Pooled 
rs7112413 11 10,222,076 ADM T C 0.20 
0.80 
(0.16) 
2x10-7 34,076 0.19 
0.18 
(0.19) 
0.33 28,856 
0.55 
(0.12) 
4x10-6 62,932 
rs11191548 10* 104,836,168 CYP17A1 T C 0.91 
1.17 
(0.23) 
3x10-7 33,123 0.92 
1.05 
(0.27) 
9x10-5 28,204 
1.12 
(0.17) 
1x10-10 61,326 
rs12725199 1 97,005,813 PTBLP, DPYD C A 0.74 
0.68 
(0.15) 
4x10-6 33,826 0.74 
0.07 
(0.17) 
0.67 28,692 
0.42 
(0.11) 
2x10-4 62,518 
rs12946454 17 40,563,647 PLCD3 T A 0.28 
0.68 
(0.15) 
4x10-6 32,120 0.27 
0.50 
(0.17) 
4x10-3 27,693 
0.60 
(0.11) 
7x10-8 59,813 
rs12676935 8 69,047,290 DEPDC2 G C 0.50 
0.60 
(0.13) 
5x10-6 30,563 0.53 
0.14 
(0.15) 
0.37 27,285 
0.40 
(0.10) 
5x10-5 57,848 
rs932764 10 95,885,930 PLCE1 G A 0.43 
0.58 
(0.13) 
6x10-6 33,920 0.43 
0.36 
(0.15) 
0.02 28,796 
0.49 
(0.10) 
6x10-7 62,716 
rs6930230 6 112,170,175 FYN T C 0.55 
0.58 
(0.13) 
7x10-6 33,288 0.58 
0.12 
(0.15) 
0.44 28,105 
0.39 
(0.10) 
8x10-5 61,393 
rs11581614 1 110,041,045 EPS8L3 T C 0.84 
-0.80 
(0.18) 
8x10-6 33,275 0.84 
-0.12 
(0.21) 
0.56 27,646 
-0.51 
(0.14) 
2x10-4 60,920 
rs3121685 5 65,697,889 SFRS12, MAST4 T C 0.50 
-0.57 
(0.13) 
1x10-5 32,321 0.49 
-0.21 
(0.15) 
0.16 28,013 
-0.42 
(0.10) 
2x10-5 60,333 
rs17367504 1 11,797,044 MTHFR, NPPA G A 0.14 
-0.79 
(0.18) 
1x10-5 34,158 0.16 
-0.85 
(0.20) 
3x10-5 29,064 
-0.81 
(0.13) 
1x10-9 63,222 
Diastolic blood pressure Global BPgen CHARGE Pooled   
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rs16998073 4 81,541,520 FGF5 T A 0.21 
0.65 
(0.11) 
7x10-9 26,106 0.24 
0.36 
(0.12) 
3x10-3 22,009 
0.51 
(0.08) 
4x10-10 48,115 
rs1378942 15* 72,864,420 CYP1A2 C A 0.36 
0.48 
(0.09) 
6x10-8 34,126 0.33 
0.43 
(0.09) 
3x10-6 29,046 
0.46 
(0.06) 
1x10-12 63,172 
rs653178 12* 110,470,476 ATXN2 T C 0.53 
-0.46 
(0.09) 
1x10-7 30,853 0.52 
-0.50 
(0.09) 
2x10-8 29,119 
-0.48 
(0.06) 
1x10-14 59,972 
rs7246865 19 17,080,105 MYO9B G A 0.75 
-0.51 
(0.10) 
7x10-7 28,918 0.74 
-0.01 
(0.11) 
0.92 26,129 
-0.27 
(0.07) 
3x10-4 55,046 
rs1530440 10 63,194,597 C10orf107 T C 0.19 
-0.51 
(0.11) 
3x10-6 32,718 0.19 
-0.44 
(0.12) 
1x10-4 27,651 
-0.48 
(0.08) 
1x10-9 60,369 
rs16916925 10* 18,508,217 CACNB2 G A 0.14 
0.58 
(0.12) 
1x10-6 33,584 0.15 
0.12 
(0.13) 
0.36 28,265 
0.36 
(0.09) 
4x10-5 61,849 
rs6544619 2 43,096,380 HAAO T C 0.44 
-0.41 
(0.09) 
2x10-6 33,922 0.44 
-0.22 
(0.09) 
0.01 28,829 
-0.32 
(0.06) 
3x10-7 62,752 
rs13231835 7 18,338,298 HDAC9 T C 0.62 
-0.45 
(0.10) 
3x10-6 26,277 0.60 
-0.13 
(0.10) 
0.16 25,718 
-0.29 
(0.07) 
2x10-5 51,995 
rs16948048 17 44,795,465 ZNF652, PHB G A 0.39 
0.40 
(0.09) 
5x10-6 34,052 0.37 
0.29 
(0.09) 
2x10-3 28,637 
0.34 
(0.06) 
5x10-8 62,688 
rs1918974 3* 170,648,590 MDS1 T C 0.54 
-0.28 
(0.09) 
1x10-3 32,674 0.53 
-0.35 
(0.09) 
8x10-5 28,307 
-0.32 
(0.06) 
3x10-7 60,981 
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Supplementary Table 4.  Gender-specific results for 8 confirmed blood pressure loci.  Shown are the 
Global BPgen gender-specific association results for the top SNP at each genome-wide significant blood pressure 
locus.  The P value for interaction between the SNP-blood pressure trait association and gender is shown.  The 
coded allele is the allele to which the beta (effect) estimate refers; for a SNP coded AA=0, AG=1, GG=2, G is the 
coded allele.  The effective sample size is shown (see methods for description) in each subsample.  Note that the 
SardiNIA sample is not included as this was analyzed in a gender-pooled analysis only with adjustment for gender 
because of its family structure. 
Trait SNP ID Chr 
Position 
NCBI35 
Coded allele 
Effect 
(SE) 
mmHg men 
P 
men 
N 
men 
Effect (SE) 
mmHg 
women 
P 
women 
N 
women 
P 
interaction 
SBP rs17367504 1 11,797,044 G 
-0.96 
(0.25) 
1x10-4 14,199 
-0.67 
(0.24) 
5x10-3 15,962 0.54 
SBP rs11191548 10 104,836,168 T 
1.10 
(0.33) 
8x10-4 13,542 
1.16 
(0.31) 
2x10-4 15,584 0.66 
SBP rs12946454 17 40,563,647 T 
0.59 
(0.21) 
5x10-3 13,400 
0.81 
(0.20) 
4x10-5 15,102 0.30 
DBP rs16998073 4 81,541,520 T 
0.47 
(0.16) 
4x10-3 10,910 
0.83 
(0.15) 
3x10-8 12,349 0.03 
DBP rs1530440 10 63,194,597 T 
-0.49 
(0.16) 
2x10-3 13,699 
-0.52 
(0.14) 
3x10-4 15,439 0.54 
DBP rs653178 12 110,470,476 T 
-0.59 
(0.13) 
3x10-6 13,121 
-0.36 
(0.12) 
2x10-3 14,812 0.37 
DBP Rs1378942 15 72,864,420 C 
0.32 
(0.13) 
1x10-2 14,199 
0.62 
(0.12) 
1x10-7 15,947 0.03 
DBP Rs16948048 17 44,795,465 G 
0.37 
(0.13) 
4x10-3 14,147 
0.43 
(0.12) 
2x10-4 15,908 0.43 
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Supplementary Methods 
Population-based GWAS samples, phenotype measurement.   
This section describes study-specific characteristics that are not presented in the 
tables. All participants provided written informed consent and studies were 
approved by local Research Ethics Committees and/or Institutional Review boards. 
   The Baltimore Longitudinal Study of Aging (BLSA) is an ongoing 
prospective study of human aging which started in 19581. The study recruited 
volunteers predominantly from Washington DC and Baltimore MD, USA. Healthy 
volunteers aged >17 years were recruited; there were no exclusion criteria. Only 
European-origin individuals were included in the analysis. Blood pressure was 
measured using a mercury sphygmomanometer in the seated position, the average 
of the 2nd and 3rd readings were recorded for both the right and left arm. 
The British 1958 Birth cohort – Type 1 Diabetes Genetics Consortium (B58C-
T1DGC) is a sample from the national population-based sample followed 
periodically from birth to age 44-45 years 
http://www.b58cgene.sgul.ac.uk/collection.php); 2,580 individuals were included in 
this analysis. Blood pressure was recorded using the Omron 705CP machine three 
times, seated. The average of three readings was used for the analysis.   
The British 1958 Birth cohort –Wellcome Trust Case Control Consortium 
(B58C-WTCCC) is a second sample from the national population-based sample 
followed periodically from birth to age 44-45 years 
(http://www.b58cgene.sgul.ac.uk/collection.php); 1,473 individuals were included 
in the analysis and are distinct from individuals included in the B58C-T1DGC cohort. 
Blood pressure was recorded using the Omron 705CP machine three times, seated. 
The average of three readings was used for the analysis. 
Cohorte Lausannoise (CoLaus) is a population-based study aimed at 
assessing the prevalence and molecular determinants of cardiovascular risk factors 
in the Caucasian population of Lausanne, Switzerland2. Participants in the study 
(4,969) were randomly selected from the population register of Lausanne in 2003 
(n=56,694, aged 35-75 years). All individuals were of Caucasian origin, defined as 
having both parents and grandparents born in a defined list of European countries. 
Blood pressure was measured using the Omron HEM-907 machine, in the seated 
position.  Three measures were taken on the left arm; the mean of the last two 
measures was used in the analyses.  
The European Prospective Investigation of Cancer- Norfolk-Genome Wide 
Association Study (EPIC-Norfolk-GWAS) study includes 3,847 participants with 
genome-wide genotyping data nested within the EPIC-Norfolk Study, a population-
based cohort study of 25,663 Europid men and women aged 39-79 years recruited 
in Norfolk, UK between 1993 and 19973,4. The 2,100 non-obese individuals were 
included in stage 1. Blood pressure was measured using the Accutorr oscillometric 
BP machine; the mean of two readings was taken and used in the analysis.  
The Fenland Study is an ongoing population-based cohort study designed to 
investigate the association between genetic and lifestyle environmental factors and 
the risk of obesity, insulin sensitivity, hyperglycemia and related metabolic traits in 
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men and women aged 30 to 55 yrs. Volunteers were recruited from General 
Practice sampling frames in the Fenland, Ely and Cambridge areas of the 
Cambridgeshire Primary Care Trust in the U.K.  The study currently comprises more 
than 3,000 participants; 1,500 volunteers were genotyped and included in the 
current analyses. Blood pressure was measured using an Accutorr automated 
sphygmomanometer; the average of three measurements made at one minute 
intervals in the seated position was used for this analysis.  
The Invecchiare in Chianti (InCHIANTI) study is a representative population-
based study of older people living in the Chianti area of Tuscany, Italy5. All 
participants were >21 years of age and of white European origin. Blood pressure 
was measured using a mercury sphygmomanometer in the supine position; the 
average of the 2nd and 3rd readings was used for the analysis.  
Kooperative Gesundheitsforschung in der Region Augsburg (KORA) (third 
survey: S3/F3) is an epidemiological cohort recruited from the general population of 
Augsburg, Germany in 1994-19956,7.  A subset of this survey (1,644 subjects) 
participated in this study (http://epi.helmholtz-muenchen.de/kora-gen/). Subjects 
with BMI<35 kg/m2 were included; diabetics were excluded. Blood pressure was 
measured using a random zero sphygmomanometer in the seated position at the 
first examination cycle; the mean of two readings was used.  
The North Finland Birth Cohort of 1966 (NFBC1966, n=12,058 live born) was 
designed to study factors affecting preterm birth, low birth weight, and subsequent 
morbidity and mortality (http://kelo.oulu.fi/NFBC/).  The longitudinal data collection 
includes clinical examination and blood sampling at age 31 years, from which data 
in the current study are drawn. The attendees in the follow-up (71% response rate) 
were adequately representative of the original cohort8 as is the final study sample 
in the present analyses. Blood pressure was measured using a mercury 
sphygmomanometer, seated, from the right arm after 15 minutes rest. The average 
of two readings taken 5 minutes apart was used for the analyses.  Both 
questionnaire and national medication reimbursement data were used for anti-
hypertensive medication information. 
The SardiNIA study is a longitudinal study examining age-related quantitative 
traits in individuals from the Ogliastra region of Sardinia, Italy9. The SardiNIA 
GWAS examined 4,305 related individuals (age >14 years), of whom 3,998 
individuals were included in this study. Blood pressure was measured using a 
mercury sphygmomanometer; the average of the second and third reading was 
used for the analyses.  
The Study of Health in Pomerania (SHIP) study is a population-based survey 
in West Pomerania, the north-east area of Germany10. A sample from the adult 
population aged 20 to 79 years was drawn based on population registries of cities 
and towns in the region. SHIP finally comprised 4,310 participants (corresponding 
to a final response rate of 68.8%). 3,310 individuals with GWAS data were included 
in this study. Blood pressure was measured three times, seated, after 5 minutes of 
rest, using a digital blood pressure monitor (HEM-705CP, Omron Corporation, 
Tokyo, Japan), after a rest period of 3 minutes for each measurement. The mean of 
the second and third measurements was used in the analyses.   
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The Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) 
study is a longitudinal study performed on a national sample of healthy volunteers 
from France between 1996 and 2001. 1,823 individuals, aged 35-65 years at 
baseline were included in this study11. Blood pressure was measured using a 
mercury sphygmomanometer in the seated position; the average of three readings 
taken from the first examination (1996) was used in the analysis.  
The TwinsUK Study comprises a sample of 1,195 healthy female Caucasians 
recruited through the TwinsUK registry in London (http://www.twin-
research.ac.uk/indexscience.html). All participants were recruited from the general 
population without presence or interest in any particular disease or trait through 
national media campaigns. One of each twin pair was selected, with ages ranging 
from 18 to 76 years. Blood pressure was measured using the Omron HEM-907 
machine, seated. Three readings were taken, the first was discarded and the 
average of the other two was used in the analyses.   
 
Control GWAS samples from case-control studies, phenotype 
measurement.   
The Diabetes Genetics Initiative (DGI) is a type 2 diabetes (T2D) case-
control study of Swedish and Finnish individuals matched on age, gender and BMI12. 
The 1,467 normoglycemic male and female controls were included in the stage 1 
Global BPgen analysis. Blood pressure traits were the average of two seated 
measurements using a mercury sphygmomanometer.  
The Finland-United States Investigation of NIDDM Genetics (FUSION) study 
aims to discover variants predisposing to T2D and T2D-related quantitative traits 
(http://fusion.sph.umich.edu/)13,14. The FUSION GWAS sample includes 1,161 
Finnish T2D cases and 1,174 normal glucose tolerant (NGT) controls and 122 
offspring of case/control pairs (1T2D, 119 NGT, 2 with impaired glucose tolerance). 
The controls and NGT offspring were used in stage 1 of the Global BPgen analysis. 
The blood pressure trait was the average of two seated measurements using a 
mercury sphygmomanometer after 5 minutes of rest15.  FUSION analyses were 
adjusted for birth province. 
 The Myocardial Infarction Genetics Consortium (MIGen) cohort is composed 
of a subset of the controls of a case-control study aimed at identifying genetic 
variants associated with early-onset myocardial infarction. Most of the controls are 
selected from population based cross-sectional or cohort studies and come from 
five different studies: Heart Attack Risk in Puget Sound (Seattle, USA), REGICOR 
(Girona, Spain), MGH Premature Coronary Artery Disease Study (Boston, USA), 
FINRISK (Finland); Malmö Diet and Cancer Study (Malmö, Sweden). For the 
majority of studies, blood pressure was measured twice using calibrated 
sphygmomanometers, in the seated position after at least 5 minutes of rest; the 
mean of the two measurements was used in the analysis. 
The Precocious Coronary Artery Disease (PROCARDIS, www.procardis.org) 
study is a European consortium investigating the genetics of precocious coronary 
artery disease (CAD) in German, Italian, Swedish and British CAD patients and 
controls16. Country of origin was a covariate in all analyses. The controls included in 
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this study had no personal history of CAD, hypertension or diabetes. Blood pressure 
was measured twice using various sphygmomanometers, in the seated position 
after at least 5 minutes of rest; the mean of the two measurements was used.  
 
Stage 2a Replication samples and phenotype measurement.  
The Utrecht Atherosclerosis Risk in Young Adults (ARYA) study is a cross 
sectional population-based birth cohort designed to assess predictors of 
cardiovascular events in young adults17. It includes 750 young adults, born in 1970-
1973 in Utrecht, The Netherlands. Blood pressure was measured using a Dinamap 
machine.  An average of 4 seated readings (two from the first visit and two from a 
second visit, mean 20 days apart) was used for the analysis. 
 The BRIGHT study is a hypertension case-control study 
(www.brightstudy.ac.uk)18. 2,445 hypertensive cases and 673 normotensive 
controls were included in this study.  Case inclusion criterion was a diagnosis of 
hypertension prior to 50 years of age (BRIGHT-HTN). Exclusion criteria included 
BMI>35, diabetes, secondary hypertension or a co-existing illness. Normotensive 
controls (BRIGHT-NT) had blood pressure recordings of SBP ≤120mmHg and DBP≤ 
85mmHg and were not taking any anti-hypertensive medications. Blood pressure 
was measured in both cohorts using the OMRON-705CP blood pressure monitor, the 
mean of three blood pressure recordings in the seated position was used in the 
analysis.  
The EPIC-Italy study is a longitudinal cohort of 10,603 volunteers, aged 35-
64 years at baseline, from the Turin area, Italy19. Individuals were excluded if they 
had anamnesis of cancer. Blood pressure was measured using a mercury 
sphygmomanometer, seated, in the left arm. 4,111 healthy subjects of both 
genders were included in this study.  
The European Prospective Investigation of Cancer-Norfolk-replication cohort 
(EPIC-Norfolk-REP) includes 15,858 participants who were not part of the genome-
wide scan in EPIC-Norfolk. These individuals were used for stage 2a follow-up; 
cohort details and blood pressure measurements are the same as described above 
for EPIC-Norfolk-GWAS.  
The Finland-United States Investigation of NIDDM Genetics (FUSION2) 
controls (n=1,162) are an independent sample from the FUSION study, these were 
used for stage 2a follow-up genotyping; cohort details and blood pressure 
measurements are same as described above for the FUSION study.  
Finrisk97 is a population-based, cross-sectional survey conducted in 1997 
designed to study the prevalence of cardiovascular risk factors in Finland.  
Genotypes were available in 7,023 men and women free of exclusions.  Blood 
pressures in Finrisk97 were averaged from 2 measures using a mercury column 
sphygmomanometer in seated participants resting for at least 5 minutes15. 
 The London Life Sciences Population (LOLIPOP) study is an ongoing population-
based cohort study of ~30,000 individuals (18,000 Indian Asians and 12,000 
European white men and women), aged 35-75 years and recruited from the lists of 
58 General Practitioners in West London, United Kingdom20,21. In the present study, 
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DNA was available for 18,829 participants. Blood pressure was measured using an 
Omron 705CP sphygmomanometer (mean of 3 measurements) with the subject 
seated.  Indian Asian analyses were adjusted for self-reported religion. 
 The Malmö Diet and Cancer (MDC) study is a community-based prospective 
epidemiologic cohort of 28,449 persons recruited for a baseline examination between 
1991 and 1996.  From this cohort, 6,103 persons were randomly selected to 
participate in the Cardiovascular Cohort (MDC-CC), which seeks to investigate risk 
factors for cardiovascular disease22. Blood pressure was measured using a mercury 
sphygmomanometer once after 10 minutes of rest in the supine position.  
 The METabolic Syndrome In Men (METSIM) study includes men aged 45–72 
years, randomly selected from the population of the town of Kuopio, Eastern 
Finland, Finland (population 95,000)23,24. The present analysis is based on the first 
~6,200 subjects examined for METSIM. Blood pressure was measured in the seated 
position after 5 minutes rest using a mercury sphygmomanometer. The average of 
3 measurements was used in the analysis.  
 The Malmö Preventive Project (MPP) is a screening program for cardiovascular 
risk factors and comprises 33,346 Swedish subjects (22,444 men and 10,902 
women) from the city of Malmö in southern Sweden25.  There are 14,600 with DNA 
after removing subjects who were also participants in MDC-CC (see above). Blood 
pressure was measured using a mercury sphygmomanometer (mean of 2 
measurements) after 10 minutes of rest supine.  
The Prevention of REnal and Vascular ENd stage Disease (PREVEND) study, is 
an ongoing prospective study investigating the natural course of increased levels of 
urinary albumin excretion and its relation to renal and cardiovascular disease. 
Inhabitants 28 to 75 years of age (n=85,421) in the city of Groningen, The 
Netherlands were asked to complete a short questionnaire; 47% responded, and 
individuals were then selected with a urinary albumin concentration of at least 10 
mg/L (n = 7,768) and a randomly selected control group with a urinary albumin 
concentration less than 10 mg/L (n = 3,395). Details of the protocol have been 
described elsewhere26,27. Blood pressure was measured in the supine position every 
minute for 10 and 8 minutes, respectively, with an automatic DINAMAP XL Model 
9300 series monitor (Critikon, Tampa, Florida).  Systolic and diastolic blood 
pressures were calculated as the mean of the last two measurements at the two 
visits. 
The Prospect-EPIC cohort is one of the two Dutch contributions to the 
European Prospective Investigation into Cancer and Nutrition (EPIC)28. Participants 
were recruited between 1993 and 1997 among women living in Utrecht and its 
vicinity and who attended the regional population-based breast cancer screening 
program. A total of 17,357 women aged 49-70 years were included. For laboratory 
analysis a 10% random sample of 1,736 samples was taken. Blood pressure was 
measured using an automated and calibrated Oscillomat (Bosch & Son, Jungingen, 
Germany); the average of two readings after 10 minutes rest in the seated position 
was used for the analysis.    
The Utrecht Health Project (UHP) is a prospective cohort of 2,829 individuals 
conducted in a newly developed residential area in the Netherlands (Leidsche 
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Rijn)29.  Blood pressure was measured using an Omron M4 machine, in the seated 
position; the average of 2 readings was used in the current analysis. 
 
Stage 2a follow-up genotyping.  For cohorts EPIC-Italy, MPP, MDC-CC, and 
EPIC-Norfolk-REP we used Taqman assays.  For Finrisk97, FUSION2 and METSIM 
samples genotyping was performed using the iPLEX Sequenom MassARRAY 
platform.  For all remaining studies we performed genotyping at KBiosciences using 
the KASPAR assay. All SNPs were in Hardy-Weinberg equilibrium (p>0.001) with 
call rate >90%. 
 
Annotation of top results.  We used a variety of tools including: UCSC genome 
browser (http://genome.ucsc.edu), HapMap (http://www.hapmap.org), OMIM 
(Online Mendelian Inheritance in Man), Medline, GeneCards 
(http://www.genecards.org), and Genesniffer (http://www.genesniffer.org). 
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study.  This work has been supported by GlaxoSmithKline, the Swiss National 
Science foundation (33CSO-122661) and and the Faculty of Biology and Medicine of 
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Contracts 263 MD 9164 13 and 263 MD 821336) and in part by the Intramural 
Research Program, National Institute on Aging, NIH, USA 
Kooperative Gesundheitsforschung in der Region Augsburg (KORA). 
Investigators: Angela Döring, Susana Eyheramendy, Christian Gieger, Thomas Illig, 
Maris Laan, Thomas Meitinger, Elin Org, Arne Pfeufer.  Principal investigator: H 
Erich Wichmann.  Study design: A.Döring, C.G., T.I., M.L., T.M., E.O.  Phenotyping: 
A.Döring.  Genotyping: T.I., T.M., E.O., A.P.  Provision of GWA data: H.E.W.  Data 
Global BPgen Supplement page 37 
 
management: C.G.  Quality control: T.I., A.P.  Data analysis: S.E., C.G.  
Interpretation: M.L., E.O., A.P.  Study coordination: M.L., H.E.W.   KORA 500K 
Blood Pressure project was supported by: Wellcome Trust International Senior 
Research Fellow (grant no. 070191/Z/03/Z) in Biomedical Science in Central Europe 
and Estonian Ministry of Education and Science core grant no. 0182721s06 (to 
M.L.), and Alexander-von-Humboldt Foundation partnership grant V-Fokoop-
1113183 (to M.L. and T.M.).  The KORA Augsburg studies were financed by the 
Helmholtz Zentrum München, German Research Center for Environmental Health, 
Neuherberg, Germany and supported by grants from the German Federal Ministry 
of Education and Research (BMBF). The KORA study group consists of H-E. 
Wichmann (speaker), A. Peters, C. Meisinger, T. Illig, R. Holle, J. John and co-
workers who are responsible for the design and conduct of the KORA studies. Part 
of this work was financed by the German National Genome Research Network 
(NGFN, T.M.). 
London Life Sciences Population study. Investigators: John C Chambers, Paul 
Elliott, Jaspal S Kooner.  Principal investigator: J.S.K.  Co-Principal Investigators: 
J.C.C., P.E. Data analysis: J.C.C.  Project management: P.E. LOLIPOP is supported 
by the British Heart Foundation Grant SP/04/002. 
Malmo Diet and Cancer-Cardiovascular Arm. Investigators: Göran Berglund, 
Olle Melander, Marju Orho-Melander.  Principal investigator of cardiovascular 
genetics: O.M.  Study origination and design: G.B.  Phenotyping: O.M.  Genotyping: 
O.M., M.O.-M.  Data analysis: O.M., M.O.-M.  This study was supported by the 
Swedish National Research Council and the Swedish Heart and Lung Foundation. 
Malmo Preventive Project. Investigators: Göran Berglund, Olle Melander, Peter 
Nilsson, Marju Orho-Melander.  Principal investigator of cardiovascular genetics: 
O.M.  Study origination and design: G.B.  Main responsibility for re-exam: P.N.  
Phenotyping: O.M.  Genotyping: O.M., M.O.-M.  Data analysis: O.M., M.O.-M.  P.N. 
is supported by the Swedish Heart and Lung Foundation and the Swedish Medical 
Research Council.    This study was supported by the Swedish National Research 
Council and the Swedish Heart and Lung Foundation. 
MIGen Study. Investigators:Gavin Lucas, Isaac Subirana, Sekar Kathiresan, 
Christopher J. O’Donnell, Veikko Salomaa, Stephen M. Schwartz, Jaume Marrugat,  
David S. Siscovick, Roberto Elosua. Other investigators: Benjamin F. Voight, Olle 
Melander, David Altshuler. Study design, sample collection and phenotyping: 
S.M.S., D.S.S., R.E., O.M., J.M., C.J.O., S.K., V.S., D.A. Data assembly: R.E., G.L., 
I.S., S.K., S.M.S. Data Analysis: G.L., I.S., B.F.V., R.E. The MIGen study was 
funded by the U.S. National Institutes of Health (NIH) and National Heart, Lung, 
and Blood Institute's STAMPEED genomics research program through a grant to 
D.A. S.K. is supported by a Doris Duke Charitable Foundation Clinical Scientist 
Development Award, a charitable gift from the Fannie E. Rippel Foundation, the 
Donovan Family Foundation, a career development award from the NIH, and 
institutional support from the Department of Medicine and Cardiovascular Research 
Center at Massachusetts General Hospital. Genotyping was partially funded by The 
Broad Institute Center for Genotyping and Analysis, which is supported by grant 
U54 RR020278 from the National Center for Research Resources.  V.S. was 
Global BPgen Supplement page 38 
 
supported by the Sigrid Juselius Foundation and the Finnish Foundation for 
Cardiovascular Research. The REGICOR study was partially funded by the Ministerio 
de Sanidad y Consumo, Instituto de Salud Carlos III (Red HERACLES RD06/0009), 
the CIBER Epidemiología y Salud Pública, the FIS (CP05/00290), and AGAUR (SGR 
2005/00577). The HARPS study was supported by grants and contracts from the US 
NIH (R01HL056931, P30ES007033, N01-HD-1-3107). 
Metabolic Syndrome in Men. Investigators: Johanna Kuusisto, Markku Laakso. 
Project conception and design, and data acquisition: J.K. and M.L. Support for 
METSIM was provided by grant 124243 from the Academy of Finland (ML). 
Northern Finland Birth Cohort of 1966. Investigators: Lachlan Coin, Paul Elliott, 
Nelson B Freimer, Anna-Liisa Hartikainen, Marjo-Riitta Jarvelin, Mark I McCarthy, 
Paul F O’Reilly, Leena Peltonen, Anneli Pouta.  Data collection: A.-L.H., M.-R.J., A.P.  
Provision of GWA data: P.E., N.B.F., M.-R.J., M.I.M., L.P.  Data analysis: L.C., 
P.F.O.  Project oversight and management: P.E., M.-R.J.  We acknowledge the 
support of NHLBI grant 5R01HL087679-02 through the STAMPEED program, the 
MRC of the UK, EURO-BLCS, QLG1-CT-2000-01643, Biocenter of University of Oulu, 
ENGAGE project and grant agreement HEALTH-F4-2007-201413, Academy of 
Finland, and NIMH grant 1RL1MH083268-01. 
PREVEND. Investigators: Paul E de Jong, Gerjan Navis, Harold Snieder, Pim van 
der Harst, Wiek H van Gilst.  Coordination of genetic studies: G.N., W.H.v.G.  
Principal investigator: P.E.d.J.  Study establishment: P.E.d.J., G.N., W.H.v.G.  Data 
acquisition: P.E.d.J., G.N., P.v.d.H., W.H.v.G.  Genotyping: P.v.d.H.  Data analysis: 
H.S., P.v.d.H.  PREVEND genetics is supported by the Dutch Kidney Foundation 
(Grant E033), EU project grant GENECURE (FP-6 LSHM CT 2006 037697), and NWO 
VENI (grant number 916.76.170). 
PROCARDIS. Investigators: Robert Clarke, Martin Farrall, Anuj Goel, Anders 
Hamsten, Simon C Heath, G Mark Lathrop, John F Peden, Udo Seedorf, Ann-
Christine Syvänen, Giovanni Tognoni, Hugh Watkins.  Principal investigator for 
project: H.W.  Principal investigators for collection centre: R.C., A.H., U.S., G.T.  
Genotyping: S.C.H., G.M.L., A.-C.S.  Quality control: S.C.H.  Data analysis: M.F., 
A.G., J.F.P.  Project management: J.F.P., H.W.  We are grateful to the participants 
and to the medical and nursing staff who assisted in this project. This work was 
funded by the British Heart Foundation, EC Sixth Framework Programme (LSHM-
CT-2007-037273), AstraZeneca AB, the Swedish Research Council (8691), the 
Swedish Heart-Lung Foundation, the Stockholm County Council (562183) and the 
Knut and Alice Wallenberg Foundation.  See www.procardis.org for full membership 
of PROCARDIS consortium. 
PROSPECT-EPIC. Investigators: N Charlotte Onland-Moret, Yvonne T van der 
Schouw.  Study conception and design, Data acquisition: N.C.O.-M., Y.T.v.d.S.  
Prospect-EPIC was funded by the European Commission - Europe Against Cancer: 
WHO AEP/90/05; The Dutch Ministry of Health; The Dutch Prevention Funds; the LK 
Research Funds; and the WCRF funds (WCRF 98A04 and WCRF 2000/30).  
Genotyping for this project was funded through an Incentive Grant from the Board 
of the UMC Utrecht. 
Global BPgen Supplement page 39 
 
SardiNIA. Investigators: Gonçalo R. Abecasis, Vesela Gateva, Edward G Lakatta, 
Samer S Najjar, Serena Sanna, Paul Scheet, David Schlessinger, Angelo Scuteri, 
Manuela Uda.  Study Design: E.G.L., D.S., M.U.  Supervision of Blood Pressure 
Phenotyping: S.S.N., A.S.  Supervision of Genotyping: M.U.  Data analysis: V.G., 
S.S., P.S.  The efforts of G.R.A. were supported in part by contract 263-MA-410953 
from the National Institute on Aging to the University of Michigan and by research 
grants from the National Human Genome Research Institute and the National Heart, 
Lung, and Blood Institute.  The SardiNIA team was supported by Contract NO1-AG-
1-2109 from the National Institute on Aging. This work was supported, in part, by 
the Intramural Research Program of the National Institute on Aging, National 
Institutes of Health. 
Study of Health in Pomerania (SHIP). Investigators: Alexander Teumer, Georg 
Homuth, Florian Ernst, Uwe Völker, Marcus Dörr, Thorsten Reffelmann, Stephan B. 
Felix, Rainer Rettig, Roberto Lorbeer, Henry Völzke. Study design: U.V., G.H., M.D., 
T.R., S.B.F., R.R., R.L., H.V; Sample collection and phenotyping: M.D., R.R., R.L., 
H.V.  DNA sample coordination: A.T., G.H., F.E., U.V; Analysis:  A.T., G.H., F.E., 
U.V. SHIP is part of the Community Medicine Research net of the University of 
Greifswald, Germany, which is funded by the Federal Ministry of Education and 
Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of 
Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-
West Pomerania. Genome-wide data have been supported by the Federal Ministry 
of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens 
Healthcare, Erlangen, Germany and the Federal State of Mecklenburg- West 
Pomerania. The University of Greifswald is a member of the ‘Center of Knowledge 
Interchange’ program of the Siemens AG. 
Supplementation en Vitamines et Minéraux Antioxydants. Investigators: Pilar 
Galan, Ivo G Gut, Simon C Heath, Serge Hercberg, Toby Johnson, G Mark Lathrop, 
Pierre Meneton, Diana Zeleneka.  Created the cohort: P.G., S.H.  Genotyping: 
S.C.H., G.M.L., I.G.G., D.Z.  Quality control: S.C.H.  Data analysis: S.C.H., T.J., 
P.M.  Project coordination: P.M.  This work has been supported by the Commissariat 
à l’Energie Atomique, the Institut National de la Santé et de la Recherche Médicale, 
the Institut National de la Recherche Agronomique and the Conservatoire National 
des Arts et Métiers. 
TwinsUK. Investigators: Panos Deloukas , Nicole Soranzo, Tim D Spector, Frances 
M Williams, Guangju Zhai, Feng Zhang.  Principal investigator: T.D.S.  Study 
design, Genome-wide association sampling: P.D.  Phenotyping: F.M.W.  
Genotyping: P.D.  Principal data analyst: F.Z.  Data analysis: N.S., G.Z.  Project 
management: P.D.  P.D. is supported by the Wellcome Trust.  This work was 
completed with support from the Wellcome Trust, and from the Department of 
Health via the National Institute for Health Research (NIHR) comprehensive 
Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in 
partnership with King's College London and King’s College Hospital NHS Foundation 
Trust. 
Utrecht Health Project. Investigators: Diederick E Grobbee, Mattijs E Numans.  
Study conception and design, and data acquisition: D.E.G., M.E.N. The UHP was 
Global BPgen Supplement page 40 
 
funded with grants the Ministry of Health, Welfare, and Sports (VWS), the 
University of Utrecht, the Province of Utrecht, the Dutch Organisation of Care 
Research (ZON), the University Medical Center of Utrecht (UMC Utrecht) and the 
Dutch College of Healthcare Insurance Companies (CVZ).  Genotyping for this 
project was funded through an Incentive Grant from the Board of the UMC Utrecht. 
Analysis group. Investigators: Gonçalo R Abecasis, Mark Caulfield, Vesela Gateva, 
Toby Johnson, Patricia B Munroe, Christopher Newton-Cheh, Martin D Tobin, Louise 
Wain. 
Writing group. Investigators: Gonçalo R Abecasis, Mark Caulfield, Paul Elliott, 
Vesela Gateva, Toby Johnson, Patricia B Munroe, Christopher Newton-Cheh, Martin 
D Tobin.  We would like to thank our colleagues at the CHARGE consortium for the 
pre-publication exchange of top results and for the enjoyable collaboration. 
Global BPgen Supplement page 41 
 
Appendix A: WTCCC Membership and affiliations 
 
Membership of the Wellcome Trust Case Control Consortium (WTCCC) 
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M Walker2, Nicholas A Watkins8,9, Thilo Winzer8, John A Todd2, Willem H 
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Sian Caesar22, Katherine Gordon-Smith22,23, Lisa Jones22; (Cardiff): Christine 
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Holmans23, Ian R Jones23, George Kirov23, Valentina Moskvina23, Ivan Nikolov23, 
Michael C O’Donovan23, Michael J Owen23, Nick Craddock23; (London): David A 
Collier24, Amanda Elkin24, Anne Farmer24, Richard Williamson24, Peter McGuffin24; 
(Newcastle): Allan H Young25, I Nicol Ferrier25  
Coronary Artery Disease (Leeds): Stephen G Ball26, Anthony J Balmforth26, 
Jennifer H Barrett26, D Timothy Bishop26, Mark M Iles26, Azhar Maqbool26, Nadira 
Yuldasheva26, Alistair S Hall26; (Leicester): Peter S Braund10, Paul R Burton1, 
Richard J Dixon10, Massimo Mangino10, Suzanne Stevens10, Martin D Tobin1, John R 
Thompson1, Nilesh J Samani10  
Crohn’s Disease (Cambridge): Francesca Bredin27, Mark Tremelling27, Miles 
Parkes27; (Edinburgh): Hazel Drummond28, Charles W Lees28, Elaine R Nimmo28, 
Jack Satsangi28; (London): Sheila A Fisher29, Alastair Forbes30, Cathryn M Lewis29, 
Clive M Onnie29, Natalie J Prescott29, Jeremy Sanderson31, Christopher G Mathew29; 
(Newcastle): Jamie Barbour32, M Khalid Mohiuddin32, Catherine E Todhunter32, 
John C Mansfield32; (Oxford): Tariq Ahmad33, Fraser R Cummings33, Derek P 
Jewell33  
Hypertension (Aberdeen): John Webster34; (Cambridge): Morris J Brown35, 
David G Clayton2; (Evry, France): G Mark Lathrop36; (Glasgow): John Connell37, 
Anna Dominiczak37; (Leicester): Nilesh J Samani10; (London): Carolina A Braga 
Marcano38, Beverley Burke38, Richard Dobson38, Johannie Gungadoo38, Kate L Lee38, 
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Patricia B Munroe38, Stephen J Newhouse38, Abiodun Onipinla38, I Wallace38, 
Mingzhan Xue38, Mark Caulfield38; (Oxford): Martin Farrall39 
Rheumatoid Arthritis: Anne Barton40, The Biologics in RA Genetics and Genomics 
Study Syndicate (BRAGGS) Steering Committee*, Ian N Bruce40, Hannah 
Donovan40, Steve Eyre40, Paul D Gilbert40, Samantha L Hider40, Anne M Hinks40, 
Sally L John40, Catherine Potter40, Alan J Silman40, Deborah PM Symmons40, Wendy 
Thomson40, Jane Worthington40 
Type 1 Diabetes: David G Clayton2, David B Dunger2,41, Sarah Nutland2, Helen E 
Stevens2, Neil M Walker2, Barry Widmer2,41, John A Todd2  
Type 2 Diabetes (Exeter): Timothy M Frayling42,43, Rachel M Freathy42,43, Hana 
Lango42,43, John R B Perry42,43, Beverley M Shields43, Michael N Weedon42,43, Andrew 
T Hattersley42,43; (London): Graham A Hitman44; (Newcastle): Mark Walker45; 
(Oxford): Kate S Elliott3,7, Christopher J Groves7, Cecilia M Lindgren3,7, Nigel W 
Rayner3,7, Nicholas J Timpson3,46, Eleftheria Zeggini3,7, Mark I McCarthy3,7  
Tuberculosis (Gambia): Melanie Newport47, Giorgio Sirugo47; (Oxford): Emily 
Lyons3, Fredrik Vannberg3, Adrian VS Hill3  
Ankylosing Spondylitis: Linda A Bradbury48, Claire Farrar49, Jennifer J Pointon48, 
Paul Wordsworth49, Matthew A Brown48,49 
AutoImmune Thyroid Disease: Jayne A Franklyn50, Joanne M Heward50, Matthew 
J Simmonds50, Stephen CL Gough50 
Breast Cancer: Sheila Seal51, Breast Cancer Susceptibility Collaboration (UK)*, 
Michael R Stratton51,52, Nazneen Rahman51  
Multiple Sclerosis: Maria Ban53, An Goris53, Stephen J Sawcer53, Alastair 
Compston53  
Gambian Controls (Gambia): David Conway47, Muminatou Jallow47, Melanie 
Newport47, Giorgio Sirugo47; (Oxford): Kirk A Rockett3, Dominic P Kwiatkowski3,5  
DNA, Genotyping, Data QC and Informatics (Wellcome Trust Sanger 
Institute, Hinxton): Claire Bryan5, Suzannah J Bumpstead5, Amy Chaney5, Kate 
Downes2,5, Jilur Ghori5, Rhian Gwilliam5, Sarah E Hunt5, Michael Inouye5, Andrew 
Keniry5, Emma King5, Ralph McGinnis5, Simon Potter5, Rathi Ravindrarajah5, Pamela 
Whittaker5, David Withers5, Panos Deloukas5; (Cambridge): Hin-Tak Leung2, 
Sarah Nutland2, Helen E Stevens2, Neil M Walker2, John A Todd2  
Statistics (Cambridge): Doug Easton12, David G Clayton2; (Leicester): Paul R 
Burton1, Martin D Tobin1; (Oxford): Jeffrey C Barrett3, David Evans3, Andrew P 
Morris3, Lon R Cardon3; (Oxford): Niall J Cardin11, Dan Davison11, Teresa 
Ferreira11, Joanne Pereira-Gale11, Ingeleif B Hallgrimsdóttir11, Bryan N Howie11, 
Jonathan L Marchini11, I CA Spencer11, Zhan Su11, Yik Ying Teo3,11, Damjan 
Vukcevic11, Peter Donnelly11  
PIs: David Bentley5,54, Matthew A Brown48,49, Lon R Cardon3, Mark Caulfield38, 
David G Clayton2, Alistair Compston53, Nick Craddock23, Panos Deloukas5, Peter 
Donnelly11, Martin Farrall39, Stephen CL Gough50, Alistair S Hall26, Andrew T 
Hattersley42,43, Adrian VS Hill3, Dominic P Kwiatkowski3,5, Christopher G Mathew29, 
Mark I McCarthy3,7, Willem H Ouwehand8,9, Miles Parkes27, Marcus Pembrey18,20, 
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Nazneen Rahman51, Nilesh J Samani10, Michael R Stratton51,52, John A Todd2, Jane 
Worthington40  
1 Genetic Epidemiology Group, Department of Health Sciences, University of 
Leicester, Adrian Building, University Road, Leicester, LE1 7RH, UK; 2 Juvenile 
Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation 
Laboratory, Department of Medical Genetics, Cambridge Institute for Medical 
Research, University of Cambridge, Wellcome Trust/MRC Building, Cambridge, CB2 
0XY, UK; 3 Wellcome Trust Centre for Human Genetics, University of Oxford, 
Roosevelt Drive, Oxford OX3 7BN, UK; 4 Department of Psychological Medicine, 
Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff 
CF14 4XN, UK; 5 The Wellcome Trust Sanger Institute, Wellcome Trust Genome 
Campus, Hinxton, Cambridge CB10 1SA, UK; 6 The Wellcome Trust, Gibbs Building, 
215 Euston Road, London NW1 2BE, UK; 7 Oxford Centre for Diabetes, 
Endocrinology and Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 
7LJ, UK; 8 Department of Haematology, University of Cambridge, Long Road, 
Cambridge, CB2 2PT, UK; 9 National Health Service Blood and Transplant, 
Cambridge Centre, Long Road, Cambridge, CB2 2PT, UK; 10 Department of 
Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Groby Road, 
Leicester, LE3 9QP, UK; 11 Department of Statistics, University of Oxford, 1 South 
Parks Road, Oxford OX1 3TG, UK; 12 Cancer Research UK Genetic Epidemiology 
Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK; 
13 National Health Service Blood and Transplant, Sheffield Centre, Longley Lane, 
Sheffield S5 7JN, UK; 14 National Health Service Blood and Transplant, Brentwood 
Centre, Crescent Drive, Brentwood, CM15 8DP, UK; 15 The Welsh Blood Service, Ely 
Valley Road, Talbot Green, Pontyclun, CF72 9WB, UK; 16 The Scottish National Blood 
Transfusion Service, Ellen’s Glen Road, Edinburgh, EH17 7QT, UK; 17 National 
Health Service Blood and Transplant, Southampton Centre, Coxford Road, 
Southampton, SO16 5AF, UK; 18 Avon Longitudinal Study of Parents and Children, 
University of Bristol, 24 Tyndall Avenue, Bristol, BS8 1TQ, UK; 19 Division of 
Community Health Services, St George’s University of London, Cranmer Terrace, 
London SW17 0RE, UK; 20 Institute of Child Health, University College London, 30 
Guilford St, London WC1N 1EH, UK; 21 University of Aberdeen, Institute of Medical 
Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK; 22 Department of Psychiatry, 
Division of Neuroscience, Birmingham University, Birmingham, B15 2QZ, UK; 23 
Department of Psychological Medicine, Henry Wellcome Building, School of 
Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 24 SGDP, The 
Institute of Psychiatry, King’s College London, De Crespigny Park Denmark Hill 
London SE5 8AF, UK; 25 School of Neurology, Neurobiology and Psychiatry, Royal 
Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK; 26 
LIGHT and LIMM Research Institutes, Faculty of Medicine and Health, University of 
Leeds, Leeds, LS1 3EX, UK; 27 IBD Research Group, Addenbrooke’s Hospital, 
University of Cambridge, Cambridge, CB2 2QQ, UK; 28 Gastrointestinal Unit, School 
of Molecular and Clinical Medicine, University of Edinburgh, Western General 
Hospital, Edinburgh EH4 2XU UK; 29 Department of Medical & Molecular Genetics, 
King’s College London School of Medicine, 8th Floor Guy’s Tower, Guy’s Hospital, 
London, SE1 9RT, UK; 30 Institute for Digestive Diseases, University College London 
Hospitals Trust, London, NW1 2BU, UK; 31 Department of Gastroenterology, Guy’s 
and St Thomas’ NHS Foundation Trust, London, SE1 7EH, UK; 32 Department of 
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Gastroenterology & Hepatology, University of Newcastle upon Tyne, Royal Victoria 
Infirmary, Newcastle upon Tyne, NE1 4LP, UK; 33 Gastroenterology Unit, Radcliffe 
Infirmary, University of Oxford, Oxford, OX2 6HE, UK; 34 Medicine and Therapeutics, 
Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Grampian AB9 2ZB, UK; 35 
Clinical Pharmacology Unit and the Diabetes and Inflammation Laboratory, 
University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, 
UK; 36 Centre National de Genotypage, 2, Rue Gaston Cremieux, Evry, Paris 91057.; 
37 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 
University Place, Glasgow, G12 8TA, UK; 38 Clinical Pharmacology and Barts and The 
London Genome Centre, William Harvey Research Institute, Barts and The London, 
Queen Mary’s School of Medicine, Charterhouse Square, London EC1M 6BQ, UK; 39 
Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human 
Genetics, Roosevelt Drive, Oxford OX3 7BN, UK; 40arc Epidemiology Research Unit, 
University of Manchester, Stopford Building, Oxford Rd, Manchester, M13 9PT, UK; 
41 Department of Paediatrics, University of Cambridge, Addenbrooke’s Hospital, 
Cambridge, CB2 2QQ, UK; 42 Genetics of Complex Traits, Institute of Biomedical and 
Clinical Science, Peninsula Medical School, Magdalen Road, Exeter EX1 2LU UK; 43 
Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical 
School, Barrack Road, Exeter EX2 5DU UK; 44 Centre for Diabetes and Metabolic 
Medicine, Barts and The London, Royal London Hospital, Whitechapel, London, E1 
1BB UK; 45 Diabetes Research Group, School of Clinical Medical Sciences, Newcastle 
University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; 46 The MRC 
Centre for Causal Analyses in Translational Epidemiology, Bristol University, 
Canynge Hall, Whiteladies Rd, Bristol BS2 8PR, UK; 47 MRC Laboratories, Fajara, 
The Gambia; 48 Diamantina Institute for Cancer, Immunology and Metabolic 
Medicine, Princess Alexandra Hospital, University of Queensland, Woolloongabba, 
Qld 4102, Australia; 49 Botnar Research Centre, University of Oxford, Headington, 
Oxford OX3 7BN, UK; 50 Department of Medicine, Division of Medical Sciences, 
Institute of Biomedical Research, University of Birmingham, Edgbaston, 
Birmingham B15 2TT, UK; 51 Section of Cancer Genetics, Institute of Cancer 
Research, 15 Cotswold Road, Sutton, SM2 5NG, UK; 52 Cancer Genome Project, The 
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, 
Cambridge CB10 1SA, UK; 53 Department of Clinical Neurosciences, University of 
Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK; 54 
PRESENT ADDRESS: Illumina Cambridge, Chesterford Research Park, Little 
Chesterford, Nr Saffron Walden, Essex, CB10 1XL, UK. 
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Appendix B: MIGen consortium members 
MIGen consortium 
Investigators: Stephen M. Schwartz1,2, David S. Siscovick1,2, Jean Yee1,2, Yechiel 
Friedlander3, Roberto Elosua4,5, Jaume Marrugat4, Gavin Lucas4, Isaac Subirana5,4, 
Joan Sala6, Rafael Ramos7, Christopher J O'Donnell8,9, Sekar Kathiresan10,11,12,8, 
Calum A. MacRae10,8, Veikko Salomaa13, Aki S. Havulinna13, Leena Peltonen12,14,15, 
Olle Melander16, Goran Berglund17, Benjamin F. Voight11,12,18, Joel N. Hirschhorn12,19, 
Kiran Musunuru10,11,12,8, Mark Daly11,12,8, Shaun Purcell11,12,20, Aarti Surti12, Candace 
Guiducci12, Lauren Gianniny12, Daniel Mirel12, Melissa Parkin12, Noel Burtt12, Stacey 
Gabriel12, David Altshuler11,12,8,18,19. 
Affiliations: 
1. Cardiovascular Health Research Unit, Departments of Medicine and 
Epidemiology, University of Washington, Seattle, Washington, USA 
2. Department of Epidemiology, University of Washington, Seattle, Washington, 
USA 
3. Unit of Epidemiology, Hebrew University-Hadassah School of Public Health, 
Jerusalem, Israel 
4. Cardiovascular Epidemiology and Genetics, Institut Municipal d'Investigacio 
Medica, Barcelona, Spain. 
5. CIBER Epidemiología y Salud Pública, Barcelona, Spain. 
6. Servei de Cardiologia i Unitat Coronària, Hospital de Girona Josep Trueta and 
Institut de Investigació Biomedica de Girona, Spain. 
7. Unitat de Recerca i Unitat Docent de Medicina de Familia de Girona, IDIAP Jordi 
Gol, Institut Català de la Salut, Spain. 
8. Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, 
USA. 
9. Framingham Heart Study and National, Heart, Lung, and Blood Institute, 
Framingham, Massachusetts, 01702, USA 
10. Cardiovascular Research Center and Cardiology Division, Massachusetts General 
Hospital, Boston, Massachusetts 02114, USA 
11. Center for Human Genetic Research, Massachusetts General Hospital, Boston, 
Massachusetts 02114, USA 
12. Program in Medical and Population Genetics, Broad Institute of Harvard and 
Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA. 
13. Chronic Disease Epidemiology Unit, Department of Health Promotion and 
Chronic Disease Prevention, National Public Health Institute, Helsinki 00300, 
Finland. 
14. Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK. 
15. Institute for Molecular Medicine, University of Helsinki, Helsinki 00029, Finland. 
16. Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, 
University Hospital, Malmö, Lund University, Malmö 20502, Sweden. 
17. Department of Clinical Sciences, Internal Medicine, University Hospital Malmö, 
Lund University, Malmö 20502, Sweden. 
18. Department of Molecular Biology, Massachusetts General Hospital, Boston, 
Massachusetts, 02114, USA. 
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19. Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, 
USA. 
20. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, 
Cambridge, Massachusetts, 02142, USA. 
 
Study contributions: Study design: S.M.S., D.S.S., R.E., J.M., C.J.O., S.K., V.S., 
L.P., O.M., J.N.H., M.D., S.P., D.A. Sample collection and phenotyping: Y.F., J.S., 
R.R., C.A.M., A.S.H., G.B. Data assembly: J.Y., G.L., I.S., S.K., R.E., S.M.S. 
Genotyping: A.S., C.G., L.G., D.M., M.P., N.B., S.G. Data Analysis: G.L., I.S., 
B.F.V., R.E., S.K. 
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